FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092341567> ?p ?o ?g. }

• W2092341567 endingPage "53" @default.
• W2092341567 startingPage "44" @default.
• W2092341567 abstract "Epirubicin exerts its anti-tumor effect through binding to topoisomerase IIalpha (TOP2A) and inducing DNA double-strand breaks. BRCA1 is involved in the repair of these breaks. We investigated the relationship between TOP2A or BRCA1 immunohistochemical expression and pathological response in 108 primary breast cancers treated with epirubicin-based regimens. The pCR (pathological complete response) rate for TOP2A-positive (17%) was significantly (P < 0.005) higher than for TOP2A-negative (2%), while the pCR rate for BRCA1-negative (11%) was non-significantly higher than for BRCA1-positive (5%). The pCR rate of TOP2A-positive and BRCA1-negative (30%) was significantly higher than for TOP2A-negative and BRCA1-positive (3%; P < 0.05), or TOP2A-negative and BRCA1-negative (0%; P < 0.005). The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens." @default.
• W2092341567 created "2016-06-24" @default.
• W2092341567 creator A5008946028 @default.
• W2092341567 creator A5011644667 @default.
• W2092341567 creator A5014421519 @default.
• W2092341567 creator A5025708681 @default.
• W2092341567 creator A5057780182 @default.
• W2092341567 creator A5058163170 @default.
• W2092341567 creator A5067189124 @default.
• W2092341567 creator A5070140946 @default.
• W2092341567 creator A5070207806 @default.
• W2092341567 creator A5071189878 @default.
• W2092341567 creator A5075754635 @default.
• W2092341567 creator A5076321370 @default.
• W2092341567 creator A5077260833 @default.
• W2092341567 creator A5077882995 @default.
• W2092341567 creator A5089012546 @default.
• W2092341567 date "2008-06-01" @default.
• W2092341567 modified "2023-09-24" @default.
• W2092341567 title "Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers" @default.
• W2092341567 cites W12356482 @default.
• W2092341567 cites W1503255403 @default.
• W2092341567 cites W1578891068 @default.
• W2092341567 cites W1965179553 @default.
• W2092341567 cites W1978331365 @default.
• W2092341567 cites W1999763107 @default.
• W2092341567 cites W2010871781 @default.
• W2092341567 cites W2030796899 @default.
• W2092341567 cites W2039135884 @default.
• W2092341567 cites W2044230523 @default.
• W2092341567 cites W2045653438 @default.
• W2092341567 cites W2049598883 @default.
• W2092341567 cites W2057084727 @default.
• W2092341567 cites W2065988361 @default.
• W2092341567 cites W2074230660 @default.
• W2092341567 cites W2078881615 @default.
• W2092341567 cites W2096471659 @default.
• W2092341567 cites W2100149631 @default.
• W2092341567 cites W2112031278 @default.
• W2092341567 cites W2115171989 @default.
• W2092341567 cites W2131915049 @default.
• W2092341567 cites W2133764807 @default.
• W2092341567 cites W2138605195 @default.
• W2092341567 cites W2139510434 @default.
• W2092341567 cites W2140890046 @default.
• W2092341567 cites W2143860386 @default.
• W2092341567 cites W2159935550 @default.
• W2092341567 cites W2415242901 @default.
• W2092341567 cites W4236530034 @default.
• W2092341567 cites W4244497714 @default.
• W2092341567 cites W4296465570 @default.
• W2092341567 doi "https://doi.org/10.1016/j.canlet.2008.01.015" @default.
• W2092341567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18280644" @default.
• W2092341567 hasPublicationYear "2008" @default.
• W2092341567 type Work @default.
• W2092341567 sameAs 2092341567 @default.
• W2092341567 citedByCount "10" @default.
• W2092341567 countsByYear W20923415672012 @default.
• W2092341567 countsByYear W20923415672013 @default.
• W2092341567 countsByYear W20923415672014 @default.
• W2092341567 countsByYear W20923415672016 @default.
• W2092341567 countsByYear W20923415672021 @default.
• W2092341567 crossrefType "journal-article" @default.
• W2092341567 hasAuthorship W2092341567A5008946028 @default.
• W2092341567 hasAuthorship W2092341567A5011644667 @default.
• W2092341567 hasAuthorship W2092341567A5014421519 @default.
• W2092341567 hasAuthorship W2092341567A5025708681 @default.
• W2092341567 hasAuthorship W2092341567A5057780182 @default.
• W2092341567 hasAuthorship W2092341567A5058163170 @default.
• W2092341567 hasAuthorship W2092341567A5067189124 @default.
• W2092341567 hasAuthorship W2092341567A5070140946 @default.
• W2092341567 hasAuthorship W2092341567A5070207806 @default.
• W2092341567 hasAuthorship W2092341567A5071189878 @default.
• W2092341567 hasAuthorship W2092341567A5075754635 @default.
• W2092341567 hasAuthorship W2092341567A5076321370 @default.
• W2092341567 hasAuthorship W2092341567A5077260833 @default.
• W2092341567 hasAuthorship W2092341567A5077882995 @default.
• W2092341567 hasAuthorship W2092341567A5089012546 @default.
• W2092341567 hasConcept C121608353 @default.
• W2092341567 hasConcept C126322002 @default.
• W2092341567 hasConcept C147897179 @default.
• W2092341567 hasConcept C202751555 @default.
• W2092341567 hasConcept C204232928 @default.
• W2092341567 hasConcept C207886595 @default.
• W2092341567 hasConcept C2776694085 @default.
• W2092341567 hasConcept C2780835546 @default.
• W2092341567 hasConcept C2781303535 @default.
• W2092341567 hasConcept C502942594 @default.
• W2092341567 hasConcept C530470458 @default.
• W2092341567 hasConcept C54355233 @default.
• W2092341567 hasConcept C71924100 @default.
• W2092341567 hasConcept C86803240 @default.
• W2092341567 hasConceptScore W2092341567C121608353 @default.
• W2092341567 hasConceptScore W2092341567C126322002 @default.
• W2092341567 hasConceptScore W2092341567C147897179 @default.
• W2092341567 hasConceptScore W2092341567C202751555 @default.
• W2092341567 hasConceptScore W2092341567C204232928 @default.
• W2092341567 hasConceptScore W2092341567C207886595 @default.

• next